New Treatment Options in Advanced Squamous Cell Lung Cancer
- PMID: 31099625
- DOI: 10.1200/EDBK_237829
New Treatment Options in Advanced Squamous Cell Lung Cancer
Abstract
The past few years have witnessed a rapid shift in the treatments for patients with squamous cell lung cancers (SQCLCs) after the U.S. Food and Drug Administration approval of a number of immune checkpoint inhibitors as second-line therapies for patients with non-small cell lung cancers. These series of approvals marked the first substantial improvement in overall survival for patients with SQCLC in over a decade. Further gains have been made more recently with the incorporation of immune checkpoint inhibition in the first-line setting, either as monotherapy or in combination with chemotherapy. These advances have, however, exposed existing deficiencies in the management of this disease. Despite a deeper understanding of the genomic alterations that characterize SQCLCs and years of trial work targeting these alterations, personalized therapies remain out of hand. Future studies will continue to focus on identifying targeted approaches to expand the treatment options for our patients.
Similar articles
-
Immune Checkpoint Inhibitors in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer.Curr Treat Options Oncol. 2018 Jun 21;19(8):39. doi: 10.1007/s11864-018-0556-7. Curr Treat Options Oncol. 2018. PMID: 29931587 Review.
-
New options on the horizon for nononcogene addicted non-small-cell lung cancer.Future Oncol. 2018 Jun;14(13s):19-28. doi: 10.2217/fon-2018-0096. Future Oncol. 2018. PMID: 29989449 Review.
-
The use of combination immunotherapies as front-line therapy for non-small-cell lung cancer.Future Oncol. 2018 Feb;14(3):191-194. doi: 10.2217/fon-2017-0124. Epub 2018 Jan 16. Future Oncol. 2018. PMID: 29334785 No abstract available.
-
Redefining Treatment Paradigms in First-line Advanced Non-Small-Cell Lung Cancer.Clin Cancer Res. 2019 Aug 15;25(16):4881-4887. doi: 10.1158/1078-0432.CCR-18-1894. Epub 2019 Mar 25. Clin Cancer Res. 2019. PMID: 30910855 Review.
-
Current strategies incorporating immune checkpoint inhibitors for the treatment of advanced or metastatic non-small-cell lung cancers.Future Oncol. 2019 Sep;15(27):3097-3101. doi: 10.2217/fon-2018-0119. Future Oncol. 2019. PMID: 31573839 No abstract available.
Cited by
-
Clinical factors and major pathological response after neoadjuvant chemoimmunotherapy in potentially resectable lung squamous cell carcinoma.Front Oncol. 2024 Apr 12;14:1265228. doi: 10.3389/fonc.2024.1265228. eCollection 2024. Front Oncol. 2024. PMID: 38680859 Free PMC article.
-
Pacritinib inhibits glucose consumption in squamous cell lung cancer cells by targeting FLT3.Sci Rep. 2023 Jan 25;13(1):1442. doi: 10.1038/s41598-023-28576-2. Sci Rep. 2023. PMID: 36697489 Free PMC article.
-
c-Rel is a Novel Oncogene in Lung Squamous Cell Carcinoma Regulating Cell Proliferation and Migration.J Cancer. 2024 Mar 4;15(8):2329-2339. doi: 10.7150/jca.93766. eCollection 2024. J Cancer. 2024. PMID: 38495491 Free PMC article.
-
Advanced Squamous Cell Carcinoma of the Lung: Current Treatment Approaches and the Role of Afatinib.Onco Targets Ther. 2020 Sep 22;13:9305-9321. doi: 10.2147/OTT.S250446. eCollection 2020. Onco Targets Ther. 2020. PMID: 33061419 Free PMC article. Review.
-
Efficacy and Safety of the PD-1 Inhibitor Combined with Albumin-Bound Paclitaxel and Nedaplatin in Preoperative Neoadjuvant Therapy of Unresectable Stage III Lung Squamous Cell Carcinoma.Drug Des Devel Ther. 2022 Dec 14;16:4269-4277. doi: 10.2147/DDDT.S388777. eCollection 2022. Drug Des Devel Ther. 2022. PMID: 36540715 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
